Saurabh A. Rajguru

Saurabh A. Rajguru

Hematology | Oncology

705 S University Ave
Suite 500
Beaver Dam, WI 53916

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: August 14, 2024

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 06, 2024

Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Journal: Leukemia & lymphoma

Published: June 10, 2024

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Journal: Blood advances

Published: May 16, 2023

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 11, 2022

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: November 05, 2020

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 08, 2020

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2019

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 14, 2018

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Journal: British journal of haematology

Published: December 08, 2016

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Journal: British journal of haematology

Published: May 25, 2016

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

Journal: The oncologist

Published: February 10, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026